Non-genetic systemic disease with glomerulopathy as a major feature

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:567558
Who is this for?
Show terms as
3Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Non-genetic systemic disease with glomerulopathy as a major feature is a broad category of conditions where a disease affecting the whole body — not caused by a gene mutation you were born with — also seriously damages the filtering units of the kidneys, called glomeruli. The glomeruli are tiny structures that clean your blood, and when they are harmed, the kidneys can no longer do their job properly. This category includes conditions like lupus nephritis (where the immune system attacks the kidneys), diabetic nephropathy (kidney damage from long-standing diabetes), amyloidosis (where abnormal proteins build up in the kidneys), and kidney damage from infections or certain cancers. Because the underlying cause varies widely, symptoms can differ from person to person. Common signs include swelling in the legs and face, foamy or bloody urine, high blood pressure, and fatigue. Over time, kidney function may decline, sometimes leading to chronic kidney disease or kidney failure. Treatment depends on the root cause. For example, lupus-related kidney disease may be treated with immune-suppressing medicines, while diabetic kidney disease is managed by controlling blood sugar and blood pressure. Some patients may eventually need dialysis or a kidney transplant. Early diagnosis and treatment are key to protecting kidney function for as long as possible.

Key symptoms:

Swelling in the legs, ankles, feet, or around the eyesFoamy or frothy urine (a sign of protein leaking into urine)Blood in the urine, making it look pink, red, or brownHigh blood pressureFatigue and low energyDecreased amount of urineNausea or loss of appetiteDifficulty concentrating or feeling mentally foggyUnexplained weight gain from fluid buildupShortness of breath if fluid builds up in the lungs

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
May 2026Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

Mediar Therapeutics — PHASE1

TrialNOT YET RECRUITING
Apr 2026Effects of Meal Macronutrients on Postprandial Lipids

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — PHASE2

TrialNOT YET RECRUITING
Jan 2026Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Regeneron Pharmaceuticals — PHASE2

TrialRECRUITING
Feb 2025Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

TrialNOT YET RECRUITING
Oct 2024Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

Chinese PLA General Hospital — PHASE4

TrialNOT YET RECRUITING
Jul 2024Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome

Sohag University — NA

TrialRECRUITING
Jun 2023Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome

Shoichi Maruyama MD PhD — PHASE3

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Non-genetic systemic disease with glomerulopathy as a major feature.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
Phase 3
Actively Recruiting
PI: Shoichi Shoichi, PhD, MD (Nagoya University Hospital) · Sites: Anjo, Aichi-ken; Kasugai, Aichi-ken +16 more · Age: 1599 yrs
Phase 21 trial
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Phase 2
Actively Recruiting
PI: Clinical Trial Management (Regeneron Pharmaceuticals) · Sites: Little Rock, Arkansas; Northridge, California +27 more · Age: 1880 yrs
N/A1 trial
Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome
N/A
Actively Recruiting
· Sites: Sohag · Age: 214 yrs

No specialists are currently listed for Non-genetic systemic disease with glomerulopathy as a major feature.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Non-genetic systemic disease with glomerulopathy as a major feature.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Non-genetic systemic disease with glomerulopathy as a major featureForum →

No community posts yet. Be the first to share your experience with Non-genetic systemic disease with glomerulopathy as a major feature.

Start the conversation →

Latest news about Non-genetic systemic disease with glomerulopathy as a major feature

No recent news articles for Non-genetic systemic disease with glomerulopathy as a major feature.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the specific cause of my kidney damage, and how does that affect my treatment plan?,How much kidney function do I have right now, and how quickly might it decline?,What medications will I need, and what are the main side effects I should watch for?,Are there dietary changes I need to make to protect my kidneys?,What warning signs should prompt me to call you or go to the emergency room?,Is there a clinical trial or newer treatment I might be eligible for?,At what point would I need to consider dialysis or a kidney transplant, and how do I prepare for that?

Common questions about Non-genetic systemic disease with glomerulopathy as a major feature

What is Non-genetic systemic disease with glomerulopathy as a major feature?

Non-genetic systemic disease with glomerulopathy as a major feature is a broad category of conditions where a disease affecting the whole body — not caused by a gene mutation you were born with — also seriously damages the filtering units of the kidneys, called glomeruli. The glomeruli are tiny structures that clean your blood, and when they are harmed, the kidneys can no longer do their job properly. This category includes conditions like lupus nephritis (where the immune system attacks the kidneys), diabetic nephropathy (kidney damage from long-standing diabetes), amyloidosis (where abnormal

How is Non-genetic systemic disease with glomerulopathy as a major feature inherited?

Non-genetic systemic disease with glomerulopathy as a major feature follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Non-genetic systemic disease with glomerulopathy as a major feature?

Yes — 3 recruiting clinical trials are currently listed for Non-genetic systemic disease with glomerulopathy as a major feature on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.